16 news items
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
and Hematology, Neuroscience, and Gastroenterology (GI). They also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. They focus
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
TAK
3 Jun 24
of orexin neurons, resulting in low levels of orexin neuropeptides in the brain and cerebrospinal fluid. No currently approved treatments target
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
target the underlying pathophysiology of NT1. People with NT1 suffer from excessive daytime sleepiness (EDS), cataplexy (sudden loss of muscle tone
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes
2i4l0p6
TAK
31 May 24
and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include
xdbo7iw8gh0ubgfjkzo6ybn5tx8y2q40yezaxv l6g2zd2jampb9nd20ppw
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
c5r8ejqgol35h1k7qzypeqe1pnsktxhc a0di7ez
ACIU
TAK
13 May 24
) announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta
ykx4gk8176n2n7c8jyfw40y8rvu2jq4x4 uqkzfvpvga
ACIU
TAK
13 May 24
Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer's disease
tcl8ekzwnap4wwfshhmu2gpycfl
ACIU
TAK
13 May 24
Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
awx0hoi7lk ah17myqnw8gdiiwkdpqssqolx5r
TAK
9 May 24
-to-Mid 30s% Target
Takeda (TYO
6mlyvl8bautf62 xmlm
TAK
26 Apr 24
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless
k960o6ldczzz2o4pfmifqrvv4m5n69rys499jwql3iqdo9d
TAK
26 Apr 24
in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over
u2g07imldsgtl03t4cuw4 jrb71jaz
TAK
18 Apr 24
regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without
ce8lr5elt2svmf68z9x9v6x5enzb59
TAK
27 Mar 24
Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We
irltbsn1op
TAK
19 Mar 24
− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (ALL
- Prev
- 1
- Next